Skip to main content

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Trial Status: Closed to Accrual

The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.

Inclusion Criteria

  • Participants must have diagnosis of a solid tumor with KRAS G12C mutation that did not respond to at least 1 line of standard therapy and has spread to other part(s) of the body
  • For phase II, participants must be willing to have new tumor tissue biopsies (doctor removes a small amount of tissue) during the study if it does not cause undue risks to health
  • Participants must be willing to use highly effective birth control
  • Participants must have adequate organ function
  • Participants must be able to swallow capsules

Exclusion Criteria

  • Participants must not have certain infections such as hepatitis or tuberculosis or HIV that is not well controlled
  • Participants must not have another serious medical condition including a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months
  • Participants must not have cancer of the central nervous system that is not stable
  • Participants must not be pregnant or breastfeeding
  • Participants must not use herbal supplements


Indiana University / Melvin and Bren Simon Cancer Center
Status: ACTIVE
Contact: Kati Lyn Dendler
Phone: 317-278-0067

New Hampshire

Dartmouth Hitchcock Medical Center

New York

New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Bob T. Li
Phone: 646-888-4201


Fred Hutch / University of Washington Cancer Consortium

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Eli Lilly and Company

  • Primary ID 17501
  • Secondary IDs NCI-2019-08221, J2K-MC-JZKA, 2019-003070-53
  • ID NCT04165031